An upcoming clinical trial will attempt to solve problems that have plagued one potentially promising treatment.
A molecule that has long been a source of hope as a potential Parkinson's disease therapy will get a new chance to show its benefit. A team led by Krystof Bankiewicz at the University of California, San Francisco, plans a clinical trial of an experimental gene therapy using glial-derived neurotrophic factor (GDNF), a protein that helps keep neurons alive. The team is in the final stages of gaining approval from the U.S. Food and Drug Administration, and hopes its trial can address issues that marred previous trials.
Source: http://feeds.technologyreview.com/click.phdo?i=e47555a0525d76c1beb810accea8fa87
No comments:
Post a Comment